A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512089-32-00

Acronym

ADCT-402-105

Enrollment

121

Registered

2024-04-09

Start date

2022-03-28

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Czechia, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026